Posted by Michael Wonder on 24 Jan 2022
Codexis announces FDA orphan drug and rare paediatric disease designations for CDX-6512 for the treatment of homocystinuria
24 January 2022 - Codexis today announced that the U.S. FDA has granted the company orphan drug designation for CDX-6512 for the treatment of homocystinuria.
CDX-6512 is a gastro-intestinal stable methionine-gamma-lyase, as a potential orally-administered enzyme therapy for homocystinuria.
The FDA also granted the company rare paediatric disease designation for CDX-6512.
